Ulcerative Colitis

A greater proportion of the upadacitinib 15 mg and upadacitinib 30 mg group achieved clinical remission based on the Crohn’s Disease Activity Index

Extended induction treatment with upadacitinib 45 mg led to achievement of clinical response in a clinically meaningful proportion of patients with ulcerative colitis who do not respond to 8 weeks of induction therapy.

Treatment with guselkumab resulted in greater improvements across key clinical and endoscopic/histologic outcome measures at week 12 compared with placebo in patients with moderately to severely active ulcerative colitis with or without a history of inadequate response or intolerance to advanced therapy.

Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.

The approval of risankizumab represents the first IL-23 approved for IBD.

A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.

The rate of serious infections was 5.9 events per 100 person-years in the placebo group, compared to 5.0 events in the upadacitinib 15 mg cohort and 3.2 upadacitinib 30 mg group.

The study results are consistent with previous meta-analyses that show the efficacy of FMT in patients with IBD compared to placebo.

Risk factors associated with inpatient mortality, included increasing age, ulcerative colitis, IBD-related surgery, pneumonia, chronic lung disease, acute kidney injury, malnutrition, frailty, heart failure, blood transfusion, sepsis/septic shock, and thromboembolism.

At 14 week, 33% of patients in the 210 mg induction etrolizumab group were in clinical remission, compared to 29% of the placebo induction group.

Several factors that impaired healing included former smoking and seton insertion.

The Qazi Corner will be a quarterly newsletter led by Taha Qazi, MD, of the Cleveland Clinic and featuring new data, conference highlights, and perspectives of leading gastroenterologists.

In total, 64.9% of patients who achieved clinical response with ustekinumab during induction were in symptomatic remission after 44 weeks.

Recent qualitative studies found social isolation in patients with IBD is 1 of the main obstacles to leading a normal life.

The FDA approved risankizumab in June for adult patients with Crohn’s disease, representing the first IL-23 treatment to be approved for this patient population.

The genus most consistently associated with Crohn’s disease was Fusobacterium, but disease-associated genera were mostly inconsistent between studies.

Patients with IBD were approximately 3.5 times more likely to have moderate or severe periodontitis.

Drs. Maia Kayal and David P. Hudesman discuss their hopes and future directions in the treatment of patients with ulcerative colitis.

Experts in gastroenterology share the clinical trial end points and metrics they use to guide their treatment of patients with ulcerative colitis.

The increase in EoE incidence was most pronounced in men and for patients aged 40 years and older.

There has been a significant increase of IBD overall and Crohn’s disease specifically in pediatric patients between 2000-2014.

There was a 25% relative reduction and a 0.3% absolute reduction in prevalence-adjusted index surgery rates for Crohn’s disease between 2007-2016.

Malnutrition rates were similar between patients with ulcerative colitis and patients with Crohn’s disease.

Maia Kayal, MD, explains how treatment guidelines can be used to direct and standardize treatment approaches in patients with ulcerative colitis.

Maia Kayal, MD, and David P. Hudesman, MD, discuss the importance of efficacy and safety data in the management of patients with ulcerative colitis and how this impacts treatment choice.

There were 248 patients included in the study with genetic data, with no differences found in mean titer after 2 or 3 doses between carriers and non-carriers of HLA-A24 associated with severe disease during COVID-19 infections.

Mesalamine use was linked to fewer relapses in the ulcerative colitis or IBD-unclassified cohorts compared to patients with Crohn’s disease.

Experts in gastroenterology provide an overview of induction vs maintenance therapy options, and comment on how their approach to treatment differs in patients with disease remission.

Maia Kayal, MD, and David P. Hudesman, MD, review their approaches to treatment in patients with ulcerative colitis.

Clinical remission at week 4 and the steroid dose reduction rate at week 4 were linked to medication discontinuation within 12 weeks.